Joint Venture
Altachem Pharma's proposed joint venture With Erdos Cashmere Group
Published in AIDS Weekly, July 1st, 2002
The proposed joint venture to be located in Beijing, China, between Altachem Pharma, Ltd., and Erdos Cashmere Corp., is in the process of regulatory approval by the necessary Chinese government regulatory authorities, announced Mr. Warren Jackson, president and CEO of Altachem Pharma, Ltd. Registered capital for preclinical development: Erdos: US$9,422,700 and Altachem: US$3,076,800 equals US$12,499,500 Registered capital for clinical trial...
The joint venture between Altachem Pharma and Erdos Cashmere Group Corp. will consist of three investment phases of registered capital totaling US$32,499,500 or the equivalent of 50,000,000 Canadian dollars:
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2002-07-01)
More Articles from AIDS Weekly
- AIDS and HIV Pathogenesis
Viral gp120 not needed for infection - Antiretroviral Therapy
Nevirapine tolerance induction safe, effective - AIDS and HIV Therapy
Cost-effectiveness of African intervention programs scrutinized - AIDS and HIV Therapy
Opioid-induced immune suppression can be prevented - IDS Therapy
Hebrew University student develops method to check if AIDS patients developed resistance to drugs - AIDS and HIV Pathogenesis
Viral Th2 cytokine expression can enhance infection - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
